Markets

Cytokinetics, Incorporated (CYTK) Jumps: Stock Up 13.5% - Tale of the Tape

Cytokinetics, Incorporated ( CYTK ) was a big mover last session, as its shares rose nearly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $8.51 to $9.90 in the past one-month timeframe.

In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cytokinetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other better-ranked stocks in the medical sector include TrovaGene, Inc. ( TROV ), ZIOPHARM Oncology, Inc. (ZIOP) and Biogen Idec Inc. ( BIIB ). All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

TROVAGENE INC (TROV): Get Free Report

ZIOPHARM ONCLGY (ZIOP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ZIOP CYTK BIIB CRDF

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More